{
    "nctId": "NCT02391818",
    "briefTitle": "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients",
    "officialTitle": "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Distorted; Balance, Quality of Life, Neuropathy, Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "Change from baseline Modified Clinical Test of Sensory Integration of Balance at 9 months.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women with breast cancer (stage 0-III)\n2. Scheduled to receive any of the following individual treatment protocols:\n\n   1. ACT\n   2. Radiation only\n\nExclusion Criteria:\n\n1. Required assistive device for ambulation in the 6 months prior to starting treatment\n2. Previous taxane or platinum chemotherapy (paclitaxel/Taxol\u00ae, docetaxel/Taxotere\u00ae, cabazitaxel/Jevtana\u00ae, cisplatin, carboplatin, and oxaliplatin)\n3. Inability to stand or walk without assistance\n4. BMI \\>40 (see chart below)\n5. Pre-existing vestibular, visual, somatosensory, orthopedic, and neurologic disease before entering the study including but not limited to being legally blind (ICD9 368.3, 369.0-369.2 lower extremity amputation (ICD9 895.0-897.7), and Diabetes (ICD9 249.0-250.93, 257.2)\n6. Evidence of central nervous system metastasis\n7. Cognitive difficulties or medical conditions that, in the opinion of the study investigators, will affect testing protocols\n8. Enrollment in other trial aimed at treating CIPN.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}